Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.95 |
| ▸ | LMNA | P02545 | 1/20 | 0.95 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.57 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.54 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.54 |
| ▸ | BLM | P54132 | 1/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | GPR84 | Q9NQS5 | 4/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.44 |
| ▸ | GRIN2D | O15399 | 1/20 | 0.44 |
| ▸ | GRIN3B | O60391 | 1/20 | 0.44 |
| ▸ | GLA | P06280 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Orotic Acid SCHEMBL29394966 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL20865 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL431534 | 0.98 | ALDH1A1 (1.00) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL16194627 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL16916880 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL23859825 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL11903511 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL9726379 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL366203 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 | |
| Orotic Acid SCHEMBL161885 | 0.95 | ALDH1A1 (0.95) | ALDH1A1LMNACYP2C19CYP1A2ALOX15 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3212191-B1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2022-10-05 | — | — | EP | claimed |
| US-11135181-B2 | Treatment for depression and depressive disorders | MEDLAB IP PTY LTD (AU) | 2021-10-05 | — | — | US | claimed |
| US-20170312232-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2017-11-02 | — | — | US | claimed |
| EP-3212191-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | Medlab IP Pty Ltd. (AU) | 2017-09-06 | — | — | EP | claimed |
| WO-2016065419-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2016-05-06 | — | — | WO | claimed |
| US-20150335688-A1 | PROBIOTIC COMBINATIONS AND USES THEREOF | MEDLAB IP PTY LTD (AU) | 2015-11-26 | — | — | US | claimed |
| US-7939109-B1 | Method of treating neoplastic disease in a human or animal patient | CARTER JOHN | 2011-05-10 | — | — | US | claimed |
| US-7758899-B2 | Pharmaceutical compositions and their use in the treatment of neoplastic disease | CARTER JOHN | 2010-07-20 | — | — | US | claimed |
| EP-1220678-B1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COPPER, SALICYLIC ACID AND VITAMIN C | CARTER JOHN (GB) | 2007-03-07 | — | — | EP | claimed |
| US-20050123623-A1 | Pharmaceutical compositions and their use in the treatment of neoplastic disease | CARTER JOHN (GB) | 2005-06-09 | — | — | US | claimed |
| EP-3212191-B1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2022-10-05 | — | — | EP | disclosed |
| US-11135181-B2 | Treatment for depression and depressive disorders | MEDLAB IP PTY LTD (AU) | 2021-10-05 | — | — | US | disclosed |
| US-20170312232-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2017-11-02 | — | — | US | disclosed |
| EP-3212191-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | Medlab IP Pty Ltd. (AU) | 2017-09-06 | — | — | EP | disclosed |
| WO-2016065419-A1 | TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS | MEDLAB IP PTY LTD (AU) | 2016-05-06 | — | — | WO | disclosed |
| US-20040170701-A1 | Pharmaceutical composition comprising copper, salicylic acid, vitamin c and zinc for use in treatment of different diseases such as bacterial or viral infection | CARTER JOHN (GB) | 2004-09-02 | — | — | US | disclosed |
| EP-1372676-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COPPER, SALICYLIC ACID, VITAMIN C AND ZINC FOR USE IN TREATMENT OF DIFFERENT DISEASES SUCH AS BACTERIAL OR VIRAL INFECTION | Carter, John (GB) | 2004-01-02 | — | — | EP | disclosed |
| WO-2002080942-A1 | PHARMACEUTICAL COMPOSITION COMPRISING COPPER, SALICYCLIC ACID, VITAMIN C AND ZINC FOR USE IN TREATMENT OF DIFFERENT DISEASES SUCH AS BACTERIAL OR VIRAL INFECTION | CARTER JOHN (GB) | 2002-10-17 | — | — | WO | disclosed |
| EP-1220678-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING COPPER, SALICYLIC ACID AND VITAMIN C | Carter, John (GB) | 2002-07-10 | — | — | EP | disclosed |
| WO-2001024803-A2 | PHARMACEUTICAL COMPOSITIONS CONTAINING COPPER, SALICYLIC ACID AND VITAMINES C | CARTER JOHN (GB) | 2001-04-12 | — | — | WO | disclosed |